133 results about "Xerophthalmia" patented technology

The invention relates to eye drops containing exosomes and a preparation method and application thereof, and belongs to the technical field of eye drop preparation, the eye drops comprise exosome freeze-dried powder, the exosome freeze-dried powder is prepared from the exosomes obtained after mesenchymal stem cells are treated with TNF-alpha and IFN-alpha, and a herba houttuyniae extract, the eye drops provided by the invention can inhibit the phenotype of macrophage M1 and promote the M1 to be converted into the phenotype of M2; human corneal cell proliferation, migration and damage repair are promoted; mouse cornea injury repair is accelerated; the eye drops can be used for treating xerophthalmia, conjunctivitis and keratitis, and can also be used for preventing eye diseases and relieving asthenopia; the eye drops disclosed by the invention contain the exosome obtained after the mesenchymal stem cells are treated by the TNF-alpha and the IFN-alpha, so that the anti-inflammatory ability is stronger; the mesenchymal stem cell exosome and the herba houttuyniae extract are stored in a freeze-dried form, so that the activity is stable, and the storage time is long; in addition, the cordate houttuynia is cooperated with the exosome, so that the effect playing time can be prolonged, and the use frequency is reduced.

The invention discloses carboxymethyl chitosan-hyaluronic acid-stem cell exosome eye drops as well as a preparation method and application thereof, and relates to the technical field of eye drops and medical biogel. The carboxymethyl chitosan-hyaluronic acid-stem cell exosome eye drops are prepared from tannic acid modified carboxymethyl chitosan and adipose tissue-derived stromal cell exosome freeze-dried powder, the carboxymethyl chitosan-hyaluronic acid-stem cell exosome eye drops provided by the invention can effectively treat xerophthalmia, and are stable in components, safe and reliable. The three components including the tannic acid modified carboxymethyl chitosan, the hyaluronic acid and the adipose tissue-derived stromal cell exosome coexist, so that the functions of all the components can be fully played, a synergistic effect is achieved, and a better treatment effect on xerophthalmia is achieved.

The invention relates to the technical field of biological medicine, in particular to eye drops containing recombinant protein as well as a preparation method and application of the eye drops. Comprising the following components: 0.01%-1% of recombinant human TFF3 protein, 0.1%-1% of an osmotic pressure regulator, 0.08%-2% of a pH regulator, 0.05%-0.15% of a thickening agent, 0.01%-0.1% of a surfactant, 0.01%-0.1% of a protective agent and the balance of water for injection, the traditional Chinese medicine composition can be used for treating the xerophthalmia, can promote wound healing and cell migration, has the effects of inhibiting inflammation and cell apoptosis, and can act on a plurality of target spots at the same time, so that the tear film stability is improved, ocular surface inflammation is inhibited, the vicious circle of the xerophthalmia is broken, and the xerophthalmia is treated more comprehensively and effectively; the problems that in the prior art, xerophthalmia medicine targets are single, and xerophthalmia cannot be comprehensively and effectively treated are solved.

The invention discloses application of a saussurea involucrata bacterial agent in fermentation of Chinese wolfberry fruits and a product thereof, and relates to the technical field of microbial fermentation. Research finds that when the saussurea involucrata bacterium agent is applied to fermentation of the Chinese wolfberry fruits, a novel Chinese wolfberry fruit deep processing product can be developed. Experiments prove that compared with the fructus lycii primary pulp, the fructus lycii deep processing product can remarkably improve the symptoms of the xerophthalmia, specifically, the tear secretion amount is increased, the tear film rupture time is prolonged, and corneal epithelium injury is reduced. According to the method, the saussurea involucrata is adopted as a fermentation strain to ferment the Chinese wolfberry primary pulp, a new Chinese wolfberry deep processing method is developed, and technical support is provided for further improving the commercial application value of the Chinese wolfberry.

The invention belongs to the field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for relieving xerophthalmia and asthenopia and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 40 to 50 parts of herba equiseti hiemalis, 30 to 40 parts of rhizoma chuanxiong, 15 to 35 parts of radix codonopsis, 20 to 25 parts of white chrysanthemum flower, 5 to 8 parts of flos carthami, 10 to 15 parts of semen celosiae, 10 to 20 parts of cortex phellodendri, 5 to 15 parts of folium artemisiae argyi, 3 to 5 parts of herba portulacae, 15 to 25 parts of herba albiziae, 0.5 to 1 part of menthol, 0.5 to 1 part of borneol and 1 to 2 parts of deep sea whole algae extract. The traditional Chinese medicine composition can effectively relieve xerophthalmia and asthenopia, and potential complication risks can be avoided.

The invention discloses an ocular surface illumination treatment device and method, and belongs to the technical field of ophthalmology medical equipment and treatment. The device comprises an infrared camera module, a computer terminal analysis control module, an optical power detection module, a mechanical adjustment module, a safety switch module and an illumination module. Wherein the infrared camera module comprises an infrared CCD (Charge Coupled Device) camera and a near-infrared light source which are arranged at a preset included angle and can collect eye images and transmit the eye images to the computer terminal, and the highest recording speed of the infrared camera module is not lower than 200 frames per second; and the computer terminal analyzes the image to obtain pupil positions, diameters and distances, and adjusts relative positions of a shielding device and a lens group in the light path of the illumination module, the axis of the light path and the distance between left and right lens cones, so that the central dark area of the annular light spot is matched and overlapped with the pupil. Eye images are collected and processed firstly, then light spots and the lens cone are adjusted, finally phototherapy and real-time monitoring are carried out, light can be prevented from entering the fundus, the treatment safety is improved, and the device is suitable for ocular surface diseases such as xerophthalmia.

The invention discloses a culture medium of a lacrimal gland organ and a culture method of the lacrimal gland organ, and the culture medium of the lacrimal gland organ is composed of a basic culture medium, R-spodin3, Noggin, B27, N-acetyl-L-cysteine, trehalose, vitamin C, glutathione, an adenylate cyclase activator, A8301, PGE2 and FGF10. The culture medium for lacrimal gland organ culture, provided by the invention, is prepared from various cell factor components according to an optimized proportion, and is simple and reasonable in components and rich in nutrition; when the culture medium is used for culturing the lacrimal gland organoid, the formation and growth of the organoid can be promoted, an in-vivo complex microenvironment is further simulated, the organoid is closer to an in-vivo physiological state, an organoid model is better constructed so as to evaluate the influence of drugs on lacrimal gland functions, and a new platform is provided for drug screening; and a new way is opened up for follow-up treatment of diseases such as xerophthalmia in the future.

The invention relates to the technical field of medical instruments, and discloses an auxiliary support for xerophthalmia treatment, which comprises a treatment eyeshade, the right side of the treatment eyeshade is provided with a transverse mounting mechanism, the right side of the transverse mounting mechanism is provided with an auxiliary mounting mechanism, and vertical mounting mechanisms are jointly arranged above and below the treatment eyeshade. The transverse mounting mechanism comprises two connecting blocks, and the side faces, close to each other, of the two connecting blocks are fixedly connected with the front face and the back face of the treatment eyeshade respectively. According to the auxiliary support for xerophthalmia treatment, through cooperation of the transverse mounting mechanism and the auxiliary mounting mechanism, the side edge vacuum suction cups are tightly connected with the side face of a patient, the side edge vacuum suction cups can be conveniently detached, and the side edge vacuum suction cups are clamped into L-shaped clamping grooves through wedge-shaped buckles; the first elastic band and the second elastic band can be connected on the side edge of the head of a patient, and the auxiliary support can be stably and conveniently disassembled and used for treating xerophthalmia.

The invention relates to a 2-substituted aminobenzothiazole compound and a pharmaceutically acceptable salt thereof, as well as a pharmaceutical composition containing the compound and application thereof. The 2-substituted aminobenzothiazole compound is a compound as shown in a general formula I and pharmaceutically acceptable salts thereof, wherein substituent groups R1, R2, R3, R4, m, n, X and Y have meanings given in the specification. The invention also relates to application of the compound shown in the general formula I in preparation of drugs for treating and / or preventing sEH-mediated diseases, in particular to application of the compound shown in the general formula I in preparation of drugs for treating inflammatory diseases, cardiovascular and cerebrovascular diseases, pain, xerophthalmia, diabetes, diabetic complications, diabetes-related diseases, fibrosis diseases, neurological and mental diseases, ulcerative diseases and the like. # imgabs0 #

The invention discloses a PDRNamp and a method for preparing the PDRNamp. The invention discloses EGT eye wash as well as a preparation method and application thereof, and belongs to the technical field of eye care products. The eye wash is prepared from the following active components in percentage by mass: 0.001 to 0.01 percent of PDRN, 0.03 to 0.1 percent of EGT (Ergothioneine), sodium hyaluronate, sodium chloride, taurine and the like, wherein the mass percent of the PDRN is 0.001 to 0.01 percent, and the mass percent of the EGT is 0.03 to 0.1 percent. Through the synergistic effect of PDRN and EGT, the product has excellent cornea repairing capacity and a powerful anti-oxidation function at the same time, and the moisturizing and soothing effects are enhanced by compounding sodium hyaluronate and taurine. The obtained eye washing liquid is an isotonic solution with neutral pH, is mild and non-irritating, does not contain preservatives, can effectively achieve multiple nursing effects of eye cleaning, moisturizing, repairing, anti-inflammatory and anti-oxidation, and is suitable for relieving xerophthalmia, assisting cornea repair and daily anti-oxidation nursing of eyes.

The invention relates to the technical field of medical equipment, and particularly discloses a xerophthalmia treatment device and method.The xerophthalmia treatment device comprises a base, a liquid medicine box is arranged in the base, a control panel is arranged at the top of the base, a placement frame is fixedly connected to the side of the base, and a treatment instrument body is placed on the placement frame; the interior of the therapeutic apparatus body is divided into a first cavity and a second cavity through a partition plate, air holes are formed in the upper inner wall and the lower inner wall of the first cavity, two eye massagers are installed on the side, close to the first cavity, of the partition plate, and an atomization therapy mechanism, an air guide mechanism and a backflow mechanism are arranged on the therapeutic apparatus body. The atomization treatment mechanism is used for sucking liquid medicine and atomizing the liquid medicine to form small particles which enter the first cavity, and the air guide mechanism is used for evenly diffusing the small particles. Massage treatment and atomization treatment are combined and can complement each other to exert respective advantages, so that the treatment effect is enhanced.

The invention belongs to the field of biological medicine, and particularly relates to a traditional Chinese medicine composition for treating xerophthalmia and relieving asthenopia and a preparation method thereof, the traditional Chinese medicine composition comprises mulberry leaf, chrysanthemum, cassia seed, wolfberry, rehmannia, dogwood, moutan bark, Chinese yam, lily, poria cocos, rhizoma alismatis, dendrobe, Chinese angelica, marigold, blueberry, lycium ruthenicum, raspberry, lutein ester and bear gall gold powder. Through the scheme, the traditional Chinese medicine composition provided by the invention can effectively treat clinical symptoms of xerophthalmia, increase tear secretion, improve fundus microcirculation and increase ciliary muscle blood flow, thereby eliminating asthenopia symptoms and improving eyesight.

The invention relates to a product suitable for treating tear film defects of xerophthalmia and a manufacturing method of the product. The invention also relates to a product for treating dry eye tear film deficiency. The product has an effect of improving wound healing in xerophthalmia and other diseases.

The invention relates to a traditional Chinese medicine composition, a pharmaceutical composition as well as a preparation method and application thereof, and the traditional Chinese medicine composition comprises the following raw materials in parts by mass: 3-15 parts of glossy privet fruit, 5-15 parts of semen cuscutae, 5-20 parts of semen cassiae, 3-13 parts of pipewort, 2-12 parts of scouring rush, 5-20 parts of radix paeoniae alba, 5-20 parts of radix puerariae and 5-15 parts of dendrobe. The pharmaceutical composition comprises the traditional Chinese medicine composition and nutrients, wherein the nutrients comprise one or more of a grape seed extract, fish oil powder and beta-carotene. After the components in the composition are reasonably combined, the composition has the advantages of being obvious in effect, lasting and stable in action and high in safety when being used for treating xerophthalmia; the traditional Chinese medicine composition can nourish liver and kidney, nourish blood and improve eyesight, clear heat and promote salivation, and regulate the functions of the body on the whole, and also can directly provide nutrient substances for eyes, improve the quality and quantity of tears, relieve eye inflammatory response, significantly relieve the symptom of xerophthalmia, and improve the living quality of patients.

The invention relates to perillaseed oil nanoemulsion eye drops as well as a preparation method and application thereof, and belongs to the technical field of medicines. The perillaseed oil nanoemulsion eye drops comprise the following raw material components in parts by mass: 1-20 parts of perillaseed oil, 0.1-10 parts of an emulsifier, 0-10 parts of a co-emulsifier, 0.05-3 parts of a metal ion chelating agent and 1-5 parts of an osmotic pressure regulator. By adding the metal ion chelating agent and controlling the preheating temperature, the problem that perillaseed oil is easy to oxidize is solved. According to the perilla oil nanoemulsion eye drops, the perilla oil serves as an effective component to exert the drug effect and also serves as an oil phase, meanwhile, the particle size of the nanoemulsion is accurately controlled by adjusting the variety of the co-emulsifier, and the safety and stability of the perilla oil nanoemulsion eye drops are further improved. The perillaseed oil eye drops provided by the invention can effectively relieve the symptoms of xerophthalmia and asthenopia, and a new medication choice is provided for treating xerophthalmia and myopia.

The invention relates to the technical field of medical preparations, in particular to moisturizing and repairing type artificial tear as well as a preparation method and application thereof. Comprising the following steps: preparing effective components including high-molecular-weight polydeoxyribonucleotide and hyaluronic acid or a salt thereof into a homogeneous-phase stable composite solution, sterilizing, filtering, and aseptically packaging, the artificial tear formed by selecting high-molecular-weight polydeoxyribonucleotide and high-molecular-weight sodium hyaluronate as effective components has a relatively good repairing effect on tissues, can form long-term moisturizing and lubrication on ocular surfaces, is suitable for treating xerophthalmia, repairing cornea, relieving inflammatory response and the like, and has a good application prospect. Important market values and clinical application prospects are realized.

The invention relates to the technical field of medicine and biology, and discloses a xerophthalmia multi-item joint detection kit which is characterized in that the kit is composed of a detection plate, sample treatment liquid, disposable tear detection filter paper strips and a drying agent, the detection plate comprises at least one detection reagent strip, and the sample treatment liquid is arranged in the detection reagent strip. The detection reagent strip is composed of a nitrocellulose membrane, a sample pad, a reagent pad, absorbent paper and a PVC (polyvinyl chloride) board, the reagent pad is a marking solution prepared by respectively marking an MMP-9 antibody, an IgE antibody and an LF antibody by a nanocarbon method, the marking solution is spread on glass fibers after being diluted by a diluent, and the glass fibers are dried overnight at 37 DEG C. According to the invention, the problems of instability and low sensitivity of colloidal gold detection products in the current market are solved. The kit is simple to operate, high in specificity during detection, high in sensitivity and visual in result, and is suitable for home self-test.

The invention belongs to the field of ophthalmology, and particularly relates to a medicament for treating moderate and severe xerophthalmia through fumigation and washing assistance, which consists of mint, schizonepeta, chrysanthemum, moutan bark, cicada slough, cassia seed and scutellaria baicalensis. The invention further provides a treatment method of the medicament for the fumigation-washing adjuvant therapy of the moderate-severe xerophthalmia, the medicament for the fumigation-washing adjuvant therapy of the moderate-severe xerophthalmia and the treatment method of the medicament can be used for patients with the moderate-severe xerophthalmia, the medicament has the main effects of dispelling wind, clearing heat, removing red spots and improving eyesight, and the medicament has the characteristics of simplicity, convenience, economy, easiness in matching and the like, and meanwhile, the medicament has the effect of treating the moderate-severe xerophthalmia through the fumigation-washing adjuvant therapy of the moderate-severe xerophthalmia. The treatment method is remarkable in treatment effect and efficient.

The invention discloses a preparation method of a non-Newtonian fluid-based temperature-shear dual response type ophthalmic sustained-release drug carrier, and belongs to the technical field of ophthalmic medicines. The preparation is composed of a dispersed phase (a temperature response type targeting nano-drug carrier) and a continuous phase (a non-Newtonian fluid matrix), wherein the mass fraction of the dispersed phase in the continuous phase is 0.5-2%. The temperature response type targeted nano-drug carrier is of a core-shell two-layer structure, the core is composed of a PLGA-PEG copolymer and an active drug, the shell is formed by grafting poly N-isopropylacrylamide (PNIPAM) and hyaluronic acid, and the lowest critical solution temperature (LCST) of the PNIPAM is 35-37 DEG C; the non-Newtonian fluid matrix is a pseudoplastic fluid, is composed of Carbomer 940 and triethanolamine, and has a shear thinning characteristic. The preparation method comprises the following three steps: preparation of the temperature response type targeting nano-drug carrier, preparation of the non-Newtonian fluid matrix and low-speed dispersion and compounding of the two. According to the invention, shear-response convenient administration, temperature-response precise drug release and long-acting retention synergism are realized, the bioavailability of the drug and the compliance of a patient are remarkably improved, the stability is excellent, the preparation process is simple and controllable, and the preparation method is suitable for long-acting targeted therapy of chronic eye diseases such as allergic conjunctivitis, chronic xerophthalmia, glaucoma and the like.

The invention provides an antioxidant collagen peptide capable of relieving xerophthalmia and a preparation method and application thereof, the amino acid sequence of the collagen peptide is GSVGEpGPL, and Ep is hydroxyproline. The collagen polypeptide disclosed by the invention has a remarkable antioxidant effect, can effectively relieve damage to eye tissues caused by oxidative stress, and shows excellent safety (low toxicity) at the same time. Besides relieving xerophthalmia caused by oxidative stress, the collagen peptide can also be widely applied to preparation of eye care compositions.

To provide an appropriate ophthalmic composition for treatment of dry eye syndrome using Tanfanercept.SOLUTION: Provided is an ophthalmic composition comprising Tanfanercept as an active ingredient for treating dry eye syndrome in a patient having moderate to severe dry eye.SELECTED DRAWING: Figure 26

The invention relates to eye drops containing umbilical cord mesenchymal stem cell exosomes. The eye drops are prepared from the following raw materials: sodium hyaluronate, an L-ascorbyl palmitate / hydroxypropyl-beta-cyclodextrin inclusion compound, panthenol, a solution containing the umbilical cord mesenchymal stem cell exosomes, water and normal saline, the concentration of the sodium hyaluronate is 0.2 to 0.6 mg / mL; the concentration of the L-ascorbyl palmitate / hydroxypropyl-beta-cyclodextrin inclusion compound ranges from 0.1 mg / mL to 0.4 mg / mL; the concentration of the panthenol is 0.2 to 1.0 mg / mL; the concentration of the umbilical cord mesenchymal stem cell exosome is 0.2 * 10 < 10 >-0.6 * 10 < 10 > parts / mL. The eye drops have good effects on treating xerophthalmia and repairing corneal epithelium injury.

The invention belongs to the technical field of medicines, and particularly relates to an active ingredient composition for treating xerophthalmia and muscae volitantes as well as a preparation method and application of the active ingredient composition. The composition is prepared from lycium barbarum polysaccharide, zeaxanthine, apigenin, luteolin, zinc gluconate, ophiopogon japonicus polysaccharide, ophiopogonin B, paeoniflorin and gallic acid according to a specific weight part ratio, all the active ingredients have a synergistic effect, the ocular surface microenvironment is improved, the vitreous opacity progress is inhibited, eye tissue damage is repaired, and the eye quality is improved. The synergistic treatment effect on the xerophthalmia and the muscae volitantes is achieved, and the symptoms such as eye dryness, eye acerbity, lacrimal secretion insufficiency, black shadow fluttering and blurred vision can be effectively relieved.

According to the application of a reagent for detecting the biomarker in preparation of a xerophthalmia diagnosis and typing detection reagent, the galectin-9 plays an important role in the occurrence and development process of the xerophthalmia, the expression level of the galectin-9 has a certain correlation with the severity of the xerophthalmia, and the galectin-9 is expected to be used as the biomarker for diagnosis and treatment of the xerophthalmia and can be used for preparing the xerophthalmia diagnosis and typing detection reagent. By detecting the expression condition of Galectin-9 in tears, early and accurate diagnosis of the dry eye and quantitative evaluation of the disease degree are achieved, in addition, Galectin-9 expressed on T cells plays an important role in immune inflammation of the dry eye, ocular surface damage of the dry eye can be relieved by locally intervening Galectin-9 through conjunctiva, and Galectin-9 serves as a novel potential target and has a good application prospect. A new way is opened up for diagnosis and treatment of xerophthalmia, a therapeutic drug or an intervention means developed for Galectin-9 can regulate immune response, inhibit inflammatory response, improve tear secretion and the like from the etiological level, and an existing xerophthalmia treatment mode is expected to be changed, so that the treatment effect is improved, the prognosis of a patient is improved, and the clinical application prospect is broad. The application prospect in the field of diagnosis and treatment of the xerophthalmia is wide, and a certain significance is achieved for improving the overall prevention and treatment level of the xerophthalmia.

The invention belongs to the field of traditional Chinese medicine, and relates to a traditional Chinese medicine composition for treating xerophthalmia, a fuming and washing agent and a preparation method and application thereof, and the traditional Chinese medicine composition for treating xerophthalmia comprises the following components in parts by weight: 20-30 parts of chrysanthemum extract dry powder, 15-20 parts of wolfberry extract dry powder, 12-18 parts of radix ophiopogonis extract dry powder and 5-10 parts of radix polygonati officinalis extract dry powder. The traditional Chinese medicine composition is prepared from 10-20 parts of radix angelicae sinensis extract dry powder, 5-15 parts of radix astragali extract dry powder, 8-14 parts of radix salviae miltiorrhizae extract dry powder, 11-17 parts of radix ampelopsis extract dry powder and 10-15 parts of sedum sarmentosum extract dry powder. The invention provides a traditional Chinese medicine composition containing chrysanthemum extract dry powder, wolfberry extract dry powder, radix ophiopogonis extract dry powder, polygonatum odoratum extract dry powder, angelica sinensis extract dry powder, astragalus membranaceus extract dry powder, salvia miltiorrhiza extract dry powder, ampelopsis japonica extract dry powder and sedum sarmentosum extract dry powder. The total effective rate of the traditional Chinese medicine composition for treating xerophthalmia can reach 90% or above.

The invention belongs to the field of ophthalmic polypeptides and drugs thereof, and provides an ophthalmic fusion polypeptide with a xerophthalmia relieving effect and an antibacterial effect at the same time, and an ophthalmic preparation containing the polypeptide. The ophthalmic fusion polypeptide provided by the invention has an antibacterial effect, and can reduce or eliminate the use of an antibacterial agent in a preparation, so that the prepared preparation has small irritation and is safer and more effective.

The invention provides an ultrasonic atomization fumigator for treating xerophthalmia in the ophthalmology department, and belongs to the field of medical instruments. Comprising a wearing machine body, telescopic binding bands are fixedly connected to the edges of the two sides of the wearing machine body, an atomization assembly capable of adjusting the liquid storage volume is arranged on one side of the bottom of the wearing machine body, and massage assemblies are arranged on the two sides of the interior of the wearing machine body; the atomization assembly comprises a first liquid storage cylinder fixed to one side of the bottom of the wearing machine body, a first threaded rod rotationally connected to the bottom of the wearing machine body and two glasses frames fixed to the inner bottom of the wearing machine body, and the outer surface of the first liquid storage cylinder is sleeved with a second liquid storage cylinder. Atomized liquid medicine can be sprayed out through the flow guide cover, wet treatment is conducted on eyes of a patient, the optimal eye protection effect is achieved, the liquid medicine can be completely used after treatment is finished by designing the variable-capacity medicine bin and adjusting the dosage according to the treatment time, and waste of the liquid medicine caused by too much liquid medicine is effectively avoided.

The invention discloses an application of a snail mucus gel purified product in preparation of a medicine for promoting corneal epithelium injury repair. The snail mucus extract is snail mucus gel purified product Z1 subtype (s-GAG Z1), and is obtained through cell and animal experiments: when the concentration of the s-GAG Z1 is 0.05 mg / mL, the cell proliferation speed is high; after the s-GAG Z1 is applied to a mouse, the cornea healing speed is higher / faster, the inflammatory cells are more / fewer, and the epithelium growth is better / better, which indicates that the s-GAG Z1 has the effects of promoting the proliferation of corneal limbal stem cells, promoting the regeneration of corneal epithelium cells and resisting inflammation in the corneal epithelium injury healing process, thereby accelerating the corneal injury healing speed. The therapeutic effect and mechanism of the s-GAG Z1 in the cornea are discussed for the first time, an experimental basis and a potential medicine are provided for clinically treating corneal ulcer, keratitis, xerophthalmia, diabetes-related keratopathy and other related corneal diseases, and toxic and side effects are avoided.

The invention discloses a polymer material based on modified collagen as well as a preparation method and application thereof, the polymer material comprises a grafted and copolymerized biocompatible material and an acrylic monomer, and the biocompatible material comprises one or a combination of the modified collagen and modified collagen peptide. The polymer material provided by the invention can realize 1.0% of collagen copolymerization amount, ensures the biocompatibility and performance of the product, and can be used as an implantable eye endoscope material; the polymer material can be obtained through polymerization under conventional initiation conditions, the cost is reduced, and the polymer material has high universality and market prospects; when the polymer material is used as an implantable eye endoscope material, the adsorption of an eye endoscope to intraocular protein can be reduced, and the possibility of problems such as infection or xerophthalmia in the eyes of a patient is effectively reduced.

The invention belongs to the technical field of biomedical engineering, and particularly relates to human corneal limbus microenvironment cell exosome eye drops as well as a preparation method and application thereof. The invention discloses human corneal limbus microenvironment cell exosome eye drops. The unique active ingredient in the eye drops is human corneal limbus microenvironment cell exosome. The invention aims to provide eye drops containing human corneal limbus microenvironment cell exosomes. The eye drops are suitable for repairing corneal injuries caused by various factors clinically and relieving eye diseases such as visual fatigue, xerophthalmia, corneal limbus stem cell deficiency and immune lesions caused by graft-versus-host diseases.